QT prolongation and near fatal cardiac arrhythmia after intravenous tacrolimus administration. A case report

Transplantation

Volumn 66, Issue 4, 1998, Pages 535-537

  Hodak, Steven P ^a   Moubarak, Jean B ^a   Rodriguez, Ignacio ^a   Gelfand, Michael C ^a   Alijani, Mohammad R ^a   Tracy, Cynthia M ^a  

^a GEORGETOWN UNIVERSITY HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CALCIUM ION; CREATINE KINASE MB; CYCLOSPORIN; PREDNISONE; TACROLIMUS;

ADULT; ARTICLE; CALCIUM CELL LEVEL; CASE REPORT; DEFIBRILLATION; ELECTROCARDIOGRAM; FEMALE; GRAFT REJECTION; HEART ARRHYTHMIA; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; INTRAVENOUS DRUG ADMINISTRATION; KIDNEY TRANSPLANTATION; LONG QT SYNDROME; PRIORITY JOURNAL; SINUS RHYTHM; TORSADE DES POINTES;

ADULT; ARRHYTHMIA; ELECTROCARDIOGRAPHY; FEMALE; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; TACROLIMUS;

EID: 0032572703     PISSN: 00411337     EISSN: None     Source Type: Journal    
DOI: 10.1097/00007890-199808270-00021     Document Type: Article

References (12)

1. Johnson MC, So S, Marsh JW, Murphy. QT prolongation and torsades de pointes after administration of FK506. Transplantation 1992; 53(4): 929.
2. Antzelevitch, C, Sun ZQ, Zhang ZQ, Van GX. Cellular and ionic mechanisms underlying erythromycin-induced long QT intervals and torsade de pointes. J Am Coll Cardiol 1996; 28: 1836.
3. McComb JM, Campbell NPS, Cleland J. Recurrent ventricular tachycardia associated with QT prolongation after mitral valve replacement and its association with intravenous administration of erythromycin. Am J Cardiol 1987; 59: 168.
4. Guelon D, Bedock B, Chartier C, Haberer JP. QT prolongation and recurrent "torsade de pointes" during erythromycin lactobionate infusion. Am J Cardiol 1986; 58: 666.
5. Locati EH, Maison-Blanche P, Dejode P, Cauchemez B, Coumel P. Spontaneous sequences of onset of torsade de pointes in patients with acquired prolonged repolarization: quantitative analysis of Holter recordings. J Am Coll Cardiol 1995; 25: 1564.
6. Jackman WM, Friday KJ, Anderson JL, Aliot EM, Clark M, Lazzara R. The long QT syndromes: a critical review, new clinical observations and a unifying hypothesis. Prog Cardiovasc Dis 1988; 31: 115.
7. Napolitano C, Priori S, Schwartz PJ. Torade de pointes. Mechanisms and management. Drugs 1994; 47(1): 51.
8. ++ overload. J Pharmacol Exp Ther 1996; 279(1): 231.
9. 2+ transients in rat cardiac myocytes. Circ Res 1996; 79(6): 1110.
10. Schwartz PJ, Moss AJ, Vincent GM, Crampton RS. Diagnostic criteria for the long QT syndrome: an update. Circulation 1993; 88: 782.
11. Vincent GM, Timothy KW, Leppert M, Keating M. The spectrum of symptoms and QT intervals in carriers of the gene for the long-QT syndrome. N Engl J Med 1992; 327: 846.
12. Shapiro R, Fung JJ, Jain AB, Parks P, Todo S, Starzl TE. The side effects of FK 506 in humans. Transplant Proc 1990; 22(1): 35.